多囊卵巢综合征 中国就医指南

Polycystic Ovary Syndrome (PCOS) is a common, complex endocrine-metabolic disorder affecting individuals of reproductive age. It is characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—though diagnosis requires at least two of these three criteria per the Rotterdam criteria, after excluding other causes of hyperandrogenism and anovulation. PCOS is not merely a gynecological condition but a systemic disorder with profound implications for metabolic, cardiovascular, and psychological health. Its pathogenesis remains incompletely understood but involves a combination of genetic predisposition, insulin resistance, compensatory hyperinsulinemia, and neuroendocrine dysregulation—particularly exaggerated luteinizing hormone (LH) pulsatility and altered gonadotropin-releasing hormone (GnRH) secretion. Insulin resistance drives ovarian theca cell androgen overproduction and impairs follicular maturation, while adipose tissue inflammation and dysbiosis may further amplify hormonal and metabolic dysfunction. Epidemiologically, PCOS affects approximately 6–12% of women globally, with prevalence varying by diagnostic criteria and population—studies in China report rates of 5.6–8.7% among reproductive-age women. Risk factors include family history (first-degree relatives with PCOS or type 2 diabetes), obesity (especially central adiposity), sedentary lifestyle, prenatal androgen exposure, and early menarche. Importantly, PCOS is strongly associated with long-term comorbidities: up to 40% develop prediabetes or type 2 diabetes by age 40; 30–50% have metabolic syndrome; and cardiovascular risk markers—including hypertension, dyslipidemia, and endothelial dysfunction—are significantly elevated. Beyond physiology, PCOS substantially impacts quality of life: menstrual irregularity, hirsutism, acne, alopecia, and infertility contribute to body image distress, anxiety, depression (prevalence 25–40%), and reduced sexual well-being. Social stigma around appearance and fertility challenges often leads to delayed help-seeking and treatment nonadherence. Early diagnosis and individualized, multidisciplinary management—spanning endocrinology, gynecology, nutrition, and mental health—are critical to mitigate both immediate symptoms and lifelong morbidity.

# 多囊卵巢综合征（PCOS）治疗方案与费用明细（内分泌科）

一、非手术保守治疗（一线首选）

• •适用人群：初诊、无生育需求或轻中度高雄/月经紊乱者
• •药物方案：

- 胰岛素增敏剂（二甲双胍缓释片）：80–220元/盒（30片），月均160–440元

• •配套检查费：性激素六项（280–420元）、OGTT+胰岛素释放（450–680元）、盆腔超声（220–350元）

二、微创介入治疗（二线选择）

• •适用人群：药物抵抗、有生育要求且LH/FSH比值＞2、卵巢间质回声增强者
• •腹腔镜下卵巢打孔术（LOD）：

- 手术费+麻醉+住院（3–5天）：12,000–18,500元

三、复杂/并发症/耐药方案

• •合并糖耐量异常/2型糖尿病：GLP-1受体激动剂（司美格鲁肽）：1,100–1,400元/支（4周用量）
• •重度不孕伴IR+高LH：联合促排卵（来曲唑+hCG触发）+代谢管理，单周期总费用3,200–5,800元

方案快速选择指南

• •预算＜3,000元/年：优选生活方式干预+二甲双胍基础治疗
• •有生育需求且药物无效：推荐LOD术（性价比最优根治路径）
• •合并糖尿病/肥胖BMI≥30：须启动GLP-1联合内分泌全程管理